s against cancer and infectious diseases, will give birth to Bayer-Schering-Pharma, n°12 in the world with 9 billion euros of turnover.
On the strategic level, the merger is completely judicious. But it will not be done without job cuts. This morning, Werner Wending, chairman of Bayer, said “the potential savings are estimated” at 6000 jobs and an annual profit of 700 million euros. Apparently, the headquarters of Bayer-Schering-Pharma should be located in Berlin, which is the current...